Vastavam web: The US-based firm Moderna Inc. has said it would ask American and European regulators to allow emergency use of its COVID-19 vaccine as new study results confirm the shots offer strong protection against the coronavirus infection. “Vaccine efficacy against COVID-19 was 94.1%; vaccine efficacy against severe infection was 100%,” the company said in a statement on Monday. Moderna said the shots’ effectiveness and a good safety record so far with only temporary, flu-like side effects mean they meet requirements set by the US Food and Drug Administration for emergency use before the final-stage testing is complete.
Since first emerging nearly a year ago in China, the virus has killed more than 1.4 million people worldwide. Moderna is just behind Pfizer and its German partner BioNTech in seeking to begin vaccinations in the US in December. Across the Atlantic, British regulators also are assessing the Pfizer shot and another from AstraZeneca. Moderna created its shots with the US National Institutes of Health and already had a hint they were working, but said it got the final needed results over the weekend that suggest the vaccine is more than 94% effective.